Literature DB >> 22041891

Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Peter Valent1, Cem Akin, Michel Arock, Knut Brockow, Joseph H Butterfield, Melody C Carter, Mariana Castells, Luis Escribano, Karin Hartmann, Philip Lieberman, Boguslaw Nedoszytko, Alberto Orfao, Lawrence B Schwartz, Karl Sotlar, Wolfgang R Sperr, Massimo Triggiani, Rudolf Valenta, Hans-Peter Horny, Dean D Metcalfe.   

Abstract

Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of 'MCA syndromes' (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D(2), or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041891      PMCID: PMC3224511          DOI: 10.1159/000328760

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  56 in total

Review 1.  Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge.

Authors:  Angela R Arredondo; Jason Gotlib; Luke Shier; Bruno Medeiros; Kathleen Wong; Athena Cherry; Christopher Corless; Daniel A Arber; Peter Valent; Tracy I George
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

2.  Mast cell activation syndrome: Proposed diagnostic criteria.

Authors:  Cem Akin; Peter Valent; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2010-10-28       Impact factor: 10.793

3.  Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.

Authors:  Iván Alvarez-Twose; David González de Olano; Laura Sánchez-Muñoz; Almudena Matito; Maria I Esteban-López; Arantza Vega; Maria Belén Mateo; Maria D Alonso Díaz de Durana; Belén de la Hoz; Maria D Del Pozo Gil; Teresa Caballero; Ana Rosado; Isabel Sánchez Matas; Cristina Teodósio; María Jara-Acevedo; Manuela Mollejo; Andrés García-Montero; Alberto Orfao; Luis Escribano
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

4.  Anaphylaxis and mast cell disease: what is the risk?

Authors:  Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.806

Review 5.  Anaphylaxis.

Authors:  F Estelle R Simons
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

Review 6.  Key advances in mechanisms of asthma, allergy, and immunology in 2009.

Authors:  Fred D Finkelman; Joshua A Boyce; Donata Vercelli; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

Review 7.  Histamine intolerance: a metabolic disease?

Authors:  H G Schwelberger
Journal:  Inflamm Res       Date:  2010-03       Impact factor: 4.575

8.  Assessing anaphylactic risk? Consider mast cell clonality.

Authors:  Dean D Metcalfe; Lawrence B Schwartz
Journal:  J Allergy Clin Immunol       Date:  2009-03       Impact factor: 10.793

9.  Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

Authors:  Christine Bodemer; Olivier Hermine; Fabienne Palmérini; Ying Yang; Catherine Grandpeix-Guyodo; Phillip S Leventhal; Smail Hadj-Rabia; Laurent Nasca; Sophie Georgin-Lavialle; Annick Cohen-Akenine; Jean-Marie Launay; Stéphane Barete; Frédéric Feger; Michel Arock; Benoît Catteau; Beatrix Sans; Jean François Stalder; Francois Skowron; Luc Thomas; Gérard Lorette; Patrice Plantin; Pierre Bordigoni; Olivier Lortholary; Yves de Prost; Alain Moussy; Hagay Sobol; Patrice Dubreuil
Journal:  J Invest Dermatol       Date:  2009-10-29       Impact factor: 8.551

Review 10.  Stinging Hymenoptera and mastocytosis.

Authors:  Franziska Ruëff; Susanne Dugas-Breit; Bernhard Przybilla
Journal:  Curr Opin Allergy Clin Immunol       Date:  2009-08
View more
  118 in total

1.  Characterization of Mast Cell Activation Syndrome.

Authors:  Lawrence B Afrin; Sally Self; Jeremiah Menk; John Lazarchick
Journal:  Am J Med Sci       Date:  2016-12-16       Impact factor: 2.378

2.  Systemic mastocytosis presenting with gastrointestinal, bone and skin involvement.

Authors:  Maria Rosignuolo; Marta Muscianese; Guglielmo Pranteda
Journal:  J Ultrasound       Date:  2014-04-08

Review 3.  Mast Cells and Anaphylaxis.

Authors:  Phil Lieberman; Lene Heise Garvey
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

Review 4.  Pathogenesis, newly recognized etiologies, and management of idiopathic anaphylaxis.

Authors:  James L Kuhlen; Yamini V Virkud
Journal:  Discov Med       Date:  2015-02       Impact factor: 2.970

Review 5.  [Surgical interventions in patients with mast cell activation disease. Aspects relevant for surgery using the example of a cholecystectomy].

Authors:  B Sido; F L Dumoulin; J Homann; H-J Hertfelder; M Bollmann; G J Molderings
Journal:  Chirurg       Date:  2014-04       Impact factor: 0.955

6.  Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose.

Authors:  Scott P Commins; Hayley R James; Whitney Stevens; Shawna L Pochan; Michael H Land; Carol King; Susan Mozzicato; Thomas A E Platts-Mills
Journal:  J Allergy Clin Immunol       Date:  2014-03-20       Impact factor: 10.793

Review 7.  Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.

Authors:  Joana Caiado; Matthieu Picard
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

8.  A 60-year-old woman with recurrent episodes of flushing, urticaria, and angioedema.

Authors:  Sheenal V Patel; James L Baldwin
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

Review 9.  Mast Cell Activation Syndrome.

Authors:  Marianne Frieri
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 10.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.